Schwendenman Andrew sold $99K of REPL

Schwendenman Andrew (Chief Accounting Officer) sold 7,632 shares of Replimune Group, Inc. (REPL) at $12.97 on 2026-08-10.

Original reporting
SEC EDGAR · Schwendenman Andrew
Published Aug 12, 2026, 9:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$REPL
Neutral
medium confidence
Mentioned
$REPL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REPLNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale details (shares, price, total value, and post-transaction holdings). No operational or financial updates are provided.

02

Market read

Traders may note the insider sale as a small sentiment datapoint, but there is no fundamental catalyst in the filing.

03

What to watch

Insider sales can be scheduled around personal events and do not reflect forward-looking valuation unless paired with other disclosures (guidance changes, financing, litigation, or clinical/regulatory milestones).

Relevance 3/10Novelty 3/10Timing: filed Aug. 12, transaction dated Aug. 10

Background

The article is an SEC Form 4 insider transaction disclosure for Replimune Group, Inc.

Company-level read

Ticker impact

$REPLNeutralMedium confidence
Context

Replimune Group disclosed an insider open-market sale by CFO Andrew Schwendenman of 7,632 shares at $12.97 on Aug. 10.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a primary-source insider transaction, but it does not include new company performance, guidance, or regulatory/contract developments. The disclosed sale size is also relatively small versus typical market-moving thresholds.

Market effects

Minimal. Insider-sale Form 4s rarely reset sector expectations without accompanying company-specific news.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan does not necessarily imply bearish intent; insiders may sell for diversification, taxes, or planned personal liquidity needs.

Key entities

  • Replimune Group, Inc.

    Company whose insider transaction was disclosed on Form 4.

  • Schwendenman Andrew

    Chief Accounting Officer who sold 7,632 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$REPLHigh

Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians

Replimune (REPL) shares rose 17% after reporting strong initial uptake of TUDRIQEV, its melanoma treatment, with over 15 institutions prescribing it in three weeks. The company has $307.8 million in cash. TUDRIQEV is used with Bristol Myers Squibb's (BMY) Opdivo and targets tumors not treated by Amgen's (AMGN) Imlygic. Analysts expect revenue growth, but no sales figures are available yet.

$REPLMed

Replimune (REPL) Q2 2027 Earnings Call Transcript

Replimune (REPL) reported Q2 2027 earnings, highlighting the commercial launch of TUDRIQEV. The company noted strong physician interest and rapid adoption, with over 15 institutions prescribing the drug in less than 20 business days. Replimune reported a net loss of $57.1 million for the quarter, with $307.8 million in cash reserves. The company expects to report first product revenue in Q3 2027.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$REPLMed

Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss

Replimune reported a net loss of $57.1M for Q2 2027, down from $83.1M a year earlier. Cash reserves were $307.8M. R&D and operating expenses decreased. TUDRIQEV, for advanced melanoma, launched commercially in the U.S. in October, with over 15 institutions prescribing it. The company is engaging with priority accounts and advancing clinical trials.